Evidence map›Paper›PMID 41711929›Full record

ArticleRevista do Instituto de Medicina Tropical de Sao Paulo2026

Rezafungin in fluconazole-resistant and refractory candidiasis: the first Brazilian experience.

Wdson Luis Lima Kruschewsky, Jeanne Aiko de Souza Nakagawa, Lumena Pereira Machado Siqueira, Mariane Taborda, Vítor Falcão de Oliveira, Edson Abdala, Adriana Satie Gonçalves Kono Magri, Marcello Mihailenko Chaves Magri

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Revista do Instituto de Medicina Tropical de Sao Paulo, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Wdson Luis Lima KruschewskyUniversidade de São Paulo, Faculdade de Medicina, Hospital das Clínicas, Divisão de Clínica de Moléstias Infecciosas e Parasitárias, São Paulo, São Paulo, Brazil.ORCID http://orcid.org/0000-0001-7094-3440
Jeanne Aiko de Souza NakagawaUniversidade de São Paulo, Faculdade de Medicina, Hospital das Clínicas, Divisão de Clínica de Moléstias Infecciosas e Parasitárias, São Paulo, São Paulo, Brazil.ORCID http://orcid.org/0009-0002-8475-2498
Lumena Pereira Machado SiqueiraUniversidade de São Paulo, Faculdade de Medicina, Hospital das Clínicas, Divisão de Laboratório Central, Seção de Microbiologia, São Paulo, São Paulo, Brazil.ORCID http://orcid.org/0000-0002-6206-2202
Mariane TabordaUniversidade de São Paulo, Faculdade de Medicina, Hospital das Clínicas, Divisão de Clínica de Moléstias Infecciosas e Parasitárias, São Paulo, São Paulo, Brazil.ORCID http://orcid.org/0000-0002-9900-9894
Vítor Falcão de OliveiraUniversidade de São Paulo, Faculdade de Medicina, Hospital das Clínicas, Divisão de Clínica de Moléstias Infecciosas e Parasitárias, São Paulo, São Paulo, Brazil.ORCID http://orcid.org/0000-0003-2097-389X
Edson AbdalaUniversidade de São Paulo, Faculdade de Medicina, Instituto do Câncer do Estado de São Paulo, São Paulo, São Paulo, Brazil.ORCID http://orcid.org/0000-0003-0765-6654
Adriana Satie Gonçalves Kono MagriUniversidade de São Paulo, Faculdade de Medicina, Hospital das Clínicas, Divisão de Clínica de Moléstias Infecciosas e Parasitárias, São Paulo, São Paulo, Brazil.ORCID http://orcid.org/0000-0001-8419-6386
Marcello Mihailenko Chaves MagriUniversidade de São Paulo, Faculdade de Medicina, Hospital das Clínicas, Divisão de Clínica de Moléstias Infecciosas e Parasitárias, São Paulo, São Paulo, Brazil.ORCID http://orcid.org/0000-0001-7996-8265

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Invasive candidiasis is associated with high morbidity and mortality, and the rising of antifungal resistance underscores the need for new therapies. Rezafungin, a second-generation echinocandin, enables once-weekly dosing, achieves high plasma concentrations, and shows potent in vitro activity. We report two Brazilian cases showing its clinical utility: (i) fluconazole-resistant Candida tropicalis bloodstream infection in a patient with colorectal cancer and chronic kidney disease and (ii) azole-refractory C. albicans esophagitis in a patient with autoimmune polyglandular syndrome type 1. Both achieved rapid clinical response and microbiological clearance. These are the first documented cases of rezafungin use for invasive candidiasis in Brazil.

Indexed as

Antifungal AgentsCandida tropicalisCandidiasis, InvasiveEchinocandinsFluconazoleAdultAgedBrazilDrug Resistance, FungalHumansMaleMicrobial Sensitivity TestsAntifungal AgentsEchinocandinsFluconazoleRezafungin

Identifiers

PMID41711929
PMCPMC12919916

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.